Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

Takashi Tokunaga, MD, Akihiro Tomita, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Kazuyuki Shimada, MD, PhD, Keiki Sugimoto, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD.

Blood (2011) 118 (21): 2659.

https://doi.org/10.1182/blood.V118.21.2659.2659

Published: 2011

Journal Articles

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

Yosuke Minami, MD, PhD, Akihiro Abe, Miho Minami, Yachiyo Kuwatsuka, Nobuaki Fukushima, Kunio Kitamura, Junji Hiraga, MD, PhD, Kazuhito Yamamoto, MD, PhD, Catriona Jamieson, Tomoki Naoe, MD, PhD

Blood (2011) 118 (21): 641.

https://doi.org/10.1182/blood.V118.21.641.641

Published: 2011

Journal Articles

Clinical Significance of Genetic Mutations of CD79B , CARD11 , MYD88 , and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients

Chisako Iriyama, MD, Akihiro Tomita, MD, PhD, Takashi Tokunaga, MD, Keisuke Sugiyama, PharmD, Junji Hiraga, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2011) 118 (21): 2633.

https://doi.org/10.1182/blood.V118.21.2633.2633

Published: 2011

Journal Articles

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

Takashi Tokunaga, MD, Akihiro Tomita, MD, PhD, Kazuyuki Shimada, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Naoe Goto, MD, PhD, Tsuyoshi Takami, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 5087.

https://doi.org/10.1182/blood.V116.21.5087.5087

Published: 2010

Journal Articles

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Akihiro Tomita, MD, PhD, Takashi Tokunaga, MD, Chisako Iriyama, MD, Kazuyuki Shimada, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Hitoshi Kiyoi, MD, PhD, Shigeo Nakamura, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 2874.

https://doi.org/10.1182/blood.V116.21.2874.2874

Published: 2010

NARROW

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

Clinical Significance of Genetic Mutations of CD79B , CARD11 , MYD88 , and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Email alerts

ASH Publications

American Society of Hematology

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

Clinical Significance of Genetic Mutations of CD79B , CARD11 , MYD88 , and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only